Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director of Race Oncology, remaining actively involved on the Board, and Dr Daniel Tillett will remain in his leadership role as Chief Scientific Officer and Executive Director.
Mr Clarke-Bruce’s deep global experience in drug commercialisation at all stages of the development process, from pre-clinical evaluation through to successful commercial launch, will be invaluable to Race’s next stage of growth. Mr Clarke-Bruce also brings an extensive network from within the pharmaceutical industry, as well as exceptional relationships with key opinion leaders across several therapeutic areas, including oncology, haematology and immunology.
“Damian has proven his commercial execution capabilities in global healthcare in a long career with companies like Pharming and Novartis – his strategic expertise, strong stakeholder engagement and energy will be key as we take our Three Pillar strategy forward.”Race Oncology Chair, Dr John Cullity
Damian, Phil and Daniel chat with Jane about Race and 2023